About Nivalis Therapeutics
Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: NVLS
- Previous Close: $2.62
- 50 Day Moving Average: $2.29
- 200 Day Moving Average: $4.93
- 52-Week Range: $15,656,000.00 - $2.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.98
- P/E Growth: 0.00
- Market Cap: $41.18M
- Outstanding Shares: 15,656,000
- Beta: -0.36
- Return on Equity: -41.72%
- Return on Assets: -39.02%
Companies Related to Nivalis Therapeutics:
- Current Ratio: 12.82%
- Quick Ratio: 12.82%
What is Nivalis Therapeutics' stock symbol?
Nivalis Therapeutics trades on the NASDAQ under the ticker symbol "NVLS."
Where is Nivalis Therapeutics' stock going? Where will Nivalis Therapeutics' stock price be in 2017?
6 brokers have issued 1 year target prices for Nivalis Therapeutics' shares. Their forecasts range from $3.00 to $20.00. On average, they expect Nivalis Therapeutics' stock price to reach $9.65 in the next twelve months.
When will Nivalis Therapeutics announce their earnings?
Nivalis Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Nivalis Therapeutics stock?
Here are some recent quotes from research analysts about Nivalis Therapeutics stock:
According to Zacks Investment Research, "Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. " (2/1/2017)
Cowen and Company analysts commented, "Nivalis reported a Q4 net loss of $6.6MM and ended 2015 with a cash balance of." (3/1/2016)
Who owns Nivalis Therapeutics stock?
Nivalis Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Deerfield Management Co. (24.01%), Kingdon Capital Management L.L.C. (3.34%) and Perceptive Advisors LLC (0.79%). Company insiders that own Nivalis Therapeutics stock include Bay Master Investors (C Hawkes, David Malcom Rodman, Global Healthcare Mas Jennison, James E Flynn, Jon Congleton, R Michael Carruthers and Robert E Conway.
Who sold Nivalis Therapeutics stock? Who is selling Nivalis Therapeutics stock?
Nivalis Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C..
Who bought Nivalis Therapeutics stock? Who is buying Nivalis Therapeutics stock?
Nivalis Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought Nivalis Therapeutics stock in the last two years include Bay Master Investors (C Hawkes, Global Healthcare Mas Jennison, James E Flynn, Jon Congleton, R Michael Carruthers and Robert E Conway.
How do I buy Nivalis Therapeutics stock?
Shares of Nivalis Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nivalis Therapeutics stock cost?
One share of Nivalis Therapeutics stock can currently be purchased for approximately $2.63.